Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Detection of BCR/ABL Fusion Gene by Hematological and Cytogenetical Analysis in Chronic Myeloid Leukemia Patients in Quetta, Pakistan

  • Tahira, Bibi (Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences) ;
  • Asif, Muhammad (Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences) ;
  • Khan, Samiullah (Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences) ;
  • Hussain, Abrar (Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences) ;
  • Shahwani, Muhammad Naeem (Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences) ;
  • Malik, Arif (Institute of Molecular Biology and Biotechnology, The University of Lahore) ;
  • Inayatullah, Syed (Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences) ;
  • Iqbal, Zafar (College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, National Guards Health Affairs) ;
  • Rasool, Mahmood (Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University)
  • Published : 2015.05.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder of pluripotent stem cells, caused by reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34;q11), known as the Philadelphia chromosome. Materials and Methods: A total of 51 CML patients were recruited in this study. Complete blood counts of all CML patients were performed to find out their total leukocytes, hemoglobin and platelets. FISH was performed for the detection of BCR-ABL fusion and cryptogenic tests using bone marrow samples were performed for the conformation of Ph (9;22)(q34;q11) and variant translocation mechanisms. Results: In cytogenetic analysis we observed that out of 51 CML patients 40 (88.9%) were Ph positive and 4 (8.88%) had Ph negative chromosomes. Mean values of WBC 134.5 $10^3/{\mu}l$, hemoglobin 10.44 mg/dl, and platelets 288.6 $10^3/{\mu}l$ were observed in this study. Conclusions: In this study, Ph positive translocation between chromosome (9:22)(q34;q11) were observed in 40 (88.9%) CML patients.

Keywords

References

  1. Achkar WA, Wafa A, Ali BY, et al (2010). A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes. Oncol Lett, 1, 797-800.
  2. Aguayo A, Garcia-Alvarez E, Cazares-Ordonez Y, et al (2008). Chronic myeloid leukemia: a clinicoepidemiologic and therapeutic description of a single institution in Mexico City. Clinical Leukemia, 2, 261-6. https://doi.org/10.3816/CLK.2008.n.036
  3. Al-Achkar W, Wafa A, Liehr T (2013). A new t (9; 11; 20; 22) (q34; p11. 2; q11. 21; q11) in a Philadelphia-positive chronic myeloid leukemia case. Oncology Letters, 5, 605-8.
  4. Al-Jamal HA, Jusoh SA, Yong AC, et al (2014). Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Asian Pac J Cancer Prev, 15, 4555-61. https://doi.org/10.7314/APJCP.2014.15.11.4555
  5. Au WY, Caguioa PB, Chuah C, et al (2009). Chronic myeloid leukemia in Asia. Int J Hematol, 89, 14-23. https://doi.org/10.1007/s12185-008-0230-0
  6. Chavan D, Ahmad F, Iyer P, et al (2006). Cytogenetic investigation in chronic myeloid leukemia: study from an Indian population. Asian Pac J Cancer Prev, 7, 423-6.
  7. Claussen U, Michel S, Muhlig P, et al (2002). Demystifying chromosome preparation and the implications for the concept of chromosome condensation during mitosis. Cytogenet Genome Res, 98, 136-46. https://doi.org/10.1159/000069817
  8. Cohen MH, Williams G, Johnson JR, et al (2002a). Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 8, 935-42.
  9. Cohen MS, Hussain HB, Moley JF (2002b). Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery, 132, 960-6; discussion 6-7. https://doi.org/10.1067/msy.2002.128562
  10. Cortes J, Giles F, O'Brien S, et al (2003). Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood, 102, 83-6. https://doi.org/10.1182/blood-2003-01-0025
  11. Cowan-Jacob SW, Fendrich G, Floersheimer A, et al (2007). Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallogr D Biol Crystallogr, 63, 80-93.
  12. Faderl S, Talpaz M, Estrov Z, et al (1999). The biology of chronic myeloid leukemia. N Engl J Med, 341, 164-72. https://doi.org/10.1056/NEJM199907153410306
  13. Jabbour E, Kantarjian HM, Jones D, et al (2009). Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood, 113, 2154-60. https://doi.org/10.1182/blood-2008-04-154344
  14. Jaiswal S, Traver D, Miyamoto T, et al (2003). Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proceed Nat Acad Sci, 100, 10002-7. https://doi.org/10.1073/pnas.1633833100
  15. Koshiyama DB, Capra ME, Paskulin GA, et al (2013). Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome. Ann Hematol, 92, 185-9. https://doi.org/10.1007/s00277-012-1598-8
  16. La Starza R, Testoni N, Lafage-Pochitaloff M, et al (2002). Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia. Haematologica, 87, 143-7.
  17. Quintas-Cardama A, Cortes JE (2006). Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc, 81, 973-88. https://doi.org/10.4065/81.7.973
  18. Sawyers CL (1999). Chronic myeloid leukemia. N Engl J Med, 340, 1330-40. https://doi.org/10.1056/NEJM199904293401706
  19. Sessarego M, Fugazza G, Bruzzone R, et al (2000). Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11. Haematologica, 85, 35-9.
  20. Simons A, Shaffer LG, Hastings RJ (2013). Cytogenetic nomenclature: changes in the ISCN 2013 compared to the 2009 edition. Cytogenet Genome Res [Epub ahead of print].
  21. Usmani SZ, Yunus SA, Jamal Y (2009). Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era. Asian Pac J Cancer Prev, 10, 1039-40.
  22. Wiernik PH (2003). Neoplastic diseases of the blood, Cambridge University Press.
  23. Ye YX, Zhou J, Zhou YH, et al (2014). Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias. Asian Pac J Cancer Prev, 15, 9961-6. https://doi.org/10.7314/APJCP.2014.15.22.9961
  24. Zangari M, Anaissie E, Stopeck A, et al (2004). Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res, 10, 88-95. https://doi.org/10.1158/1078-0432.CCR-0221-3

Cited by

  1. Multiplex RT-PCR Assay for Detection of Common Fusion Transcripts in Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Cases vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.677